In GBM, besides EGFR amplifications and mutations, IDH mutations and PTEN loss stand out as some of the most extensively investigated genetic drivers influencing the regulation of cancer cell metabolic reprogramming. The gene discussed is IDH2; the disease is glioblastoma.